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Reviewing the literature in many fields on proposed risk models reveals problems with the way many risk models
are developed. Furthermore, papers reporting new risk models do not always provide sufficient information to allow
readers to assess the merits of the model. In this review, we discuss sources of bias that can arise in risk model
development. We focus on two biases that can be introduced during data analysis. These two sources of bias are
sometimes conflated in the literature and we recommend the terms resubstitution bias and model-selection bias to
delineate them. We also propose the RiGoR reporting standard to improve transparency and clarity of published
papers proposing new risk models.
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There is currently broad interest in developing risk pre-
diction models in medicine. However, recent reviews in
a variety of fields have described a substantial number of
flaws in the way risk models are developed and/or defi-
ciencies in the way the work is reported [1-6]. An exten-
sive review that spanned many fields of application
found the vast majority of papers reporting risk models
omitted important details such as: the extent and handling
of missing data; key information on the study population;
and the precise definition of the outcome or event of
interest [6]. An evaluation of model calibration was typ-
ically absent. Additional issues include a tendency for
models to be favorably evaluated when the model’s de-
velopers are involved in validating the model [4].
Research reports related to risk prediction sometimes
refer to “optimistic bias” or “optimism bias” [4,7,8]. Un-
fortunately, these terms are used to refer to a variety of
problems in risk model development or assessment. It
would be useful to have clear, distinctive, and descriptive
names for different sources of bias that can affect scien-
tific results. The first goal of this review is to propose
terminology for referring to two sources of bias that are
common in developing risk models. Both biases can arise* Correspondence: katiek@uw.edu
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unless otherwise stated.during data analysis, which makes them avoidable, at least
in principle. The second goal of this paper is a proposal
for a set of guidelines for reporting proposed new risk
models. The guidelines should help readers evaluate the
merits of new risk models and understand whether devel-
opers were attentive to avoiding common sources of bias.Review
Common sources of bias in risk model development
Currently, two sources of bias that arise in developing
risk prediction models from combinations of biomarkers
and/or clinical variables are both called “optimistic bias.”
We propose the terms “resubstitution bias” and “model-
selection bias” as more precise and descriptive terms
than “optimistic bias.” A predictive model will tend to per-
form better on the data that were used to fit or “train” the
model than on new data. Resubstitution bias arises when
the data that are used to fit a predictive model are used a
second time to assess the performance of the model. Re-
using the data in this way has been called resubstitution
[9-15], so it is a modest extension to refer to the resulting
bias as resubstitution bias. Since the ultimate goal of a risk
prediction model is to estimate risks on new individuals,
assessing model performance via resubstitution does not
provided an unbiased or “honest” estimate of the model’s
predictive capacity.
Model-selection bias arises when many models are
assessed, and the best performing model is reported.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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rected for resubstitution bias in assessing the model.
Occasionally, investigators have a single, pre-specified
model that they fit with data. In this case, the resulting
model is susceptible to resubstitution bias but not to
model-selection bias. More typically, however, data ana-
lysts have a set of candidate predictors to choose from,
which translates to a set of possible models. For example,
if there are k candidate predictors and an analyst limits
the set of possible models to linear logistic models, then
the number of possible models is 2k-1. For 20 candidate
predictors this is over 1 million models, and we expect
some of these to perform well by chance. Naïve assess-
ment of the best-performing model is likely optimistic be-
cause this model is chosen because it performed best on
the available data [16-19]. “Model-selection bias” refers to
this particular source of optimism.
Although resubstitution bias and model-selection bias
are well-known phenomena among methodologists and
many data analysts [7,10,20], there is no standard ter-
minology for referring to these sources of bias. We find
the term “optimistic bias” inadequate for several reasons.
“Optimistic bias” describes the direction of the bias and
not the source of the bias, so it is insufficiently descrip-
tive. By referring to multiple sources of bias with the
same phrase researchers might claim to have addressed
“optimistic bias” in developing a predictive model [21],
when in fact they have only addressed one source of bias.
Finally, in addition to resubstitution and model-selection
there are additional phenomena referred to as “optimistic
bias” [8], including the observation in psychology that
people often underestimate personal risks [22].
We emphasize that resubstitution bias and model-
selection bias are well-known among methodologists,
and our modest contribution is our proposal for standard
terms to refer to these issues. These terms have appeared
occasionally (and rarely) in the literature [17,23,24] but
are not in widespread use. Previously proposed termin-
ology is “parameter uncertainty” and “model uncertainty
[20], where “model uncertainty” is said to lead to “selection
bias.” However, this terminology is not standard and we
find it less descriptive than the terms we propose. Further-
more, “selection bias” has an established meaning in epi-
demiology, where it refers to non-representative selection
of study subjects.
Methodology for estimating the performance of a risk
model that is not optimistically biased from resubstitu-
tion includes bootstrapping techniques, cross-validation,
and using independent datasets for model development
and validation [7,25]. Bootstrapping and cross-validation
are computationally intensive, and employing them can
surpass the abilities of some data analysts or software
packages. Moreover, there are different varieties of boot-
strapping and cross-validation and a lack of consensuson the best procedure. A recent investigation [21] pro-
vides some much-needed guidance on the relative merits
of different procedures for estimating the area under the
ROC curve (AUC or “C statistic”) without resubstitution
bias. Using independent datasets for model development
and validation is computationally simpler, and provides
stronger evidence in favor of a reported risk model if
the validation dataset is from a separate study (“external
validation”). More commonly, however, a validation dataset
is created by data splitting – randomly partitioning the
available data into a “training” dataset and a “test” or
validation dataset. This strategy offers simplicity and flexi-
bility in data analysis, but is criticized for its statistical
inefficiency [7] because only part of the data inform de-
velopment of the risk model. With data splitting there
is an inherent tension between the amount of data al-
lotted to the training dataset for developing the risk
model, and the amount of data allotted to the test data-
set for evaluating the risk model [26]. If the training
dataset is too small a good risk model might not be
found. On the other hand, if the test dataset is too
small then estimates of model performance, while un-
biased, are highly variable, making promising results less
compelling. An advantage of having an independent
validation dataset is that both resubstitution and model-
selection bias are accounted for as long as the validation
dataset is not used in any stage of model development,
including variable selection.
Model-selection bias tends to be more difficult to
address without an independent validation dataset. In
principle, model-selection can be incorporated into a
bootstrapping or cross-validation procedure, but this
requires the use of an automated model-building process
and further increases the computational complexity of
using these methods.
Reporting standards
There have been several efforts to develop standards and
guidelines for reporting various types of scientific studies.
As summarized by McShane and colleagues [27], quality
study reporting “cannot transform a poorly designed or
analyzed study into a good one, but it can help to identify
the poor studies.” Quality reporting is an important first
step in improving the overall quality of risk model devel-
opment work [4,6]. Reporting standards can additionally
help guide researchers toward best practices. Table 1 pre-
sents our proposed RiGoR (Reporting Guidelines for Risk
Models) Standards for reporting risk model development.
Previously published reporting standards that are related
to risk model development are STARD [28], GRIPS [29],
and REMARK [27]. The STARD initiative [28] assembled
a comprehensive set of standards “to improve the accuracy
and completeness of reporting of studies of diagnostic ac-
curacy, to allow readers to assess the potential for bias in
Table 1 RiGoR: reporting guidelines for risk models
Similar items
Section and topic Item STARD REMARK GRIPS
Title/Abstract/Keywords 1 Identify the article as reporting the development of a risk model combining
multiple predictors (MeSH “Risk”, possibly “risk factor” and/or “biomarker”)
1 1 1
Introduction 2 Identify the overarching goal – why would an effective risk model be valuable
to clinical care, public health, or research?
2 20 2
Methods
Participants 3 Describe the study subjects: The inclusion and exclusion criteria (and resulting
sample sizes), setting and locations where the data were collected. Descriptive
statistics should include variable ranges.
3 2 4,5,14
4a Describe participant recruitment. 4 5
4b Report when study was done, including beginning and ending dates of recruitment. 14 6 4
5 Describe the study design. Was this a cohort study? A case–control study? Note:
matched case control studies are generally not suitable for risk model development
unless special methods and external data are used.
5 6 4
Biomarker Data 6 Describe data collection, including timing of specimen collection for biomarker
measurement. Document where there was blinding to clinical outcomes.
8 4,5
7 Document technical specifications of biomarker materials and methods, including
marker units. Describe possibility of batch effects, storage effects, number of
freeze/thaw cycles, assay upper and lower limits. Document how biomarker values
at the limits of detection were handled.
4,5 7
8 For multi-center studies, document whether biomarker measurements can be
considered comparable between study sites, or whether lab effect, platform
differences, or variations in clinical practice may affect biomarker levels.
23
Outcome variable 9 Describe how the outcome is defined (e.g., precise definition for disease diagnosis,
or death from any cause vs. specific cause)
7 6
Statistical Methods 10 Document measures of model performance, e.g. AUC for risk models; sensitivity and
specificity for a pre-selected risk threshold; report methods to quantify uncertainty
(e.g., 95% confidence intervals via bootstrapping)
12 12
11 Document how markers were used: transformations (e.g., log)? categorization of
continuous variables? Other adjustments (e.g. kidney biomarkers adjusted for urine
creatinine)?
9 11 8
12a List all variables initially considered as candidates 8 9
12b Describe variable selection: how were variables selected to include in the risk model or
classifier? Pre-specified prior to any analysis of the data? Selected based on univariate
analysis? An exhaustive search over a set of models? Stepwise procedure?
10 9
12c Describe how model-selection bias was addressed in assessing the performance of final
reported model(s). If model-selection bias was not addressed, state this explicitly.
10
13 Document methodology used to develop risk model or classifier: logistic regression?
logic regression? relative risk regression?
10
14a Document methodology to avoid or correct for resubsitution bias in measures of the
performance of the final reported model(s).
10
14b If an independent validation “test” dataset was used, document that the test data were
not used for any part of model development, including variable selection. Document
that these data were accessed only when models were finalized. Report the number
of models evaluated on the “test” data and how these were selected.
10
14c If cross-validation is used, state how final reported model is derived. 10
15 For multi-center studies with the possibility of confounding by center, describe methods
for adjusting or accounting for center effects.
16 Describe how indeterminate results and missing data were handled, or report that there
were no indeterminate results or missing data.
22 11
17 Describe methods for assessing model calibration.
Results 18 Report clinical and demographic characteristics of the study population (e.g. age, sex,
presenting symptoms, co-morbidity, current treatments, recruitment centers).
15 13 15
19 Report final risk model or classifier
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Table 1 RiGoR: reporting guidelines for risk models (Continued)
20 Report estimates of model performance with measures of uncertainty when
possible (e.g., 95% confidence interval)
21 18,19
21 Assess and report evidence of risk model calibration.
Discussion 22 Discuss prospects of final risk model for satisfying the research goal 25 22, 23
23 Discuss known and possible limitations to generalizability or applicability
of risk model
19 21
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isability (external validity)” (http://www.stard-statement.org/).
A primary result of the initiative is a 25 item checklist
for articles reporting studies of diagnostic accuracy. The
RiGoR guidelines are meant to emulate the contribution
of STARD with a set of criteria tailored to the develop-
ment of risk prediction instruments. The REMARK
recommendations [27] were developed in the context
of tumor markers with the potential to be used for prog-
nosis. The focus of REMARK is markers for predicting
time-to-event outcomes such as overall survival. In con-
trast, the focus of RiGoR is estimating patient risks of a
binary outcome. The GRIPS statement [29] offers report-
ing standards focused on studies of risk prediction models
that include genetic variants. The RiGoR guidelines are
more general and more detailed.
In proposing the RiGoR standards, we both acknowledge
and build upon the important previous efforts described
above. For each RiGoR item, Table 1 notes similar STARD,
REMARK, or GRIPS items. As Table 1 shows, most items
are similar to criteria given in at least one of these previous
reports. However, there are some notable exceptions. First,
RiGoR includes a guideline that the calibration of a risk
prediction model should be assessed and reported, as
calibration is a necessary requirement for the validity of
a model. While the importance of calibration is noted
in many publications [6,30,31], it is not included in
GRIPS. Second, our guidelines explicitly address resub-
stitution bias and model-selection bias, two common types
of bias that can arise during risk model development.
There are items in the REMARK and GRIPS guidelines
that are not included in RiGoR. In Appendix A we docu-
ment our reasons for excluding these items.
Conclusions
In Epidemiology, common pitfalls in study design and
data analysis commonly acquire standard names. Some
examples include immortal time bias in survival analysis
[32] and lead time bias in the evaluation of diagnostic
screening tools [33]. Publication bias is a widely recognized
issue in the scientific literature [34]. The most helpful ter-
minology is descriptive; helps codify important concepts;
and aids scientific communication. We believe the terms
“resubstitution bias” and “model-selection bias” accomplish
these goals.In this article we have reviewed and discussed resub-
stitution bias and model-selection bias. We do not mean
to suggest that they are the only two sources of bias that
can affect risk model development. However, we believe
resubstitution bias and model-selection bias deserve spe-
cial attention because they are common. Furthermore,
they are biases that arise during data analysis, which
means, at least in principle, that they should be avoidable
with use of proper methods of data analysis.
Other types of bias can enter into a study at earlier
stages. For example, selection bias can inflate the perform-
ance of a proposed risk model if the cases in the dataset
tend to be more severe than the population of cases, or
controls tends to be healthier than the population of con-
trols. Having an objective way to define the population of
interest and to define the event of interest is an important
aspect of a quality study. The RiGoR standards are de-
signed to ensure that these and other important aspects of
study design, conduct, and data analysis are documented.Appendix A
We comment on items in the GRIPS and REMARK
guidelines that do not appear in the RiGoR guidelines.
Our purpose here is explain the rationale of the RiGoR
guidelines and our comments should not be interpreted
as criticisms of these important, previous efforts.GRIPS
3. “Specify the study objectives and state the specific
model(s) that is/are investigated. State if the study
concerned the development of the model(s), a validation
effort, or both.”
The RiGoR guidelines apply to papers documenting
the development of risk models.
13. “Describe all subgroups, interactions, and exploratory
analyses that were examined.”
20. “Present results of any subgroup, interaction, or
exploratory analyses, whenever pertinent.”
Item 13 is very broad, and item 20 is vague as to what
constitutes “pertinent” results. In the RiGoR guidelines,
we focus on sources of bias (e.g. model-selection bias
and resubstitution bias) that are common in risk model
development and provide specific guidelines to identify
them.
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scores.”
Such distributions are one way to evaluate model per-
formance. The RiGoR guidelines provide flexibility on
metrics by which to evaluate risk models.
24. “State whether databases for the analyzed data, risk
models, and/or protocols are or will become publicly
available and if so, how they can be accessed.”
We did not include a similar item in the RiGoR guide-
lines because it is not crucial for assessing the study that
was done.
25. “Give the source of funding and the role of the funders
for the present study. State whether there are any conflicts
of interest.”
We did not include an item like this in the RiGoR guide-
lines because it is not specific to risk model research.
REMARK
3. “Describe treatments received and how chosen (e.g.
randomized or rule-based).”
This item is specific to prognosis in cancer.
9. “Give rationale for sample size; if the study was designed
to detect a specified effect size, give the target power and
effect size.”
This guideline is more appropriate for studies of
association.
12. “Describe the flow of patients through the study, in-
cluding the number of patients included in each stage of
the analysis (a diagram may be helpful) and reasons for
dropout. Specifically, both overall and for each subgroup
extensively examined report the numbers of patients and
the number of events.”
This item is not widely applicable to risk model
development.
14. “Show the relation of the marker to standard prog-
nostic variables.”
15. “Present univariate analyses showing the relation be-
tween the marker and outcome, with the estimated effect
(e.g. hazard ratio and survival probability.) Preferably pro-
vide similar analyses for all other variables being analyzed.
For the effect of a tumor marker on a time-to-event out-
come, a Kaplan-Meier plot is recommended.”
16. “For key multivariable analyses, report estimated ef-
fects (e.g. hazard ratio) with confidence intervals for the
marker and, at least for the final model, all other vari-
ables in the model.”
17. “Among reported results, provide estimated effects
with confidence intervals from an analysis in which the
marker and standard prognostic variable are included,
regardless of their statistical significance.”
Such information is tangential to the validity and utility
of a risk model. Furthermore, in the context of extensive
variable or model selection, estimated effects may be
biased.18. “If done, report results of further investigations, such
as checking assumptions, sensitivity analyses, and internal
validation.”
This guideline is somewhat broad and open-ended, so
we chose not to include a similar item in the RiGoR
guidelines.
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